AT
Axcynsis Therapeutics is a biotechnology company focused on developing Antibody-X Conjugate (AXC) therapies for cancer treatment. The company utilizes proprietary technologies, including AxcynMAB™, AxcynCYS™, and AxcynDOT™, to build a pipeline of AXC candidates. These efforts aim to provide new treatment options addressing unmet medical needs in oncology.
Updated 4 months ago
Funding
$21M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- Axcynsis Therapeutics is a biotechnology company focused on developing Antibody-X Conjugate (AXC) therapies for cancer treatment. The company utilizes proprietary technologies, including AxcynMAB™, AxcynCYS™, and AxcynDOT™, to build a pipeline of AXC candidates. These efforts aim to provide new treatment options addressing unmet medical needs in oncology.